Allergy 'Under Review': What the Status Means

The first status period is not the full scientific review. It is the journal checking whether the record can be handled: files open correctly, author metadata is complete, disclosures are included, ethics statements are present, and the manuscript appears to match the journal's scope. For Allergy, this stage matters because a small administrative issue can look like a peer-review delay from the author's side. If the status changes quickly to Under Review, read that as a routing signal, not as proof that every reviewer has accepted.

The useful action during this stage is not to ask whether the editor likes the paper. It is to make sure every status email, submission-form field, and manuscript file points to the same claim. A mismatch between the cover letter, abstract, figure sequence, and supplementary files creates editorial friction even when the work is credible.

For Allergy, the file package should make clear that the manuscript is about an allergy-central disease question backed by both immunological mechanism and clinical relevance rather than a generic paper looking for a prestigious home before a reviewer has to reconstruct the claim.

At this point the manuscript is being read for fit. The editor is not only asking whether the manuscript is polished, but whether the manuscript makes an allergy-central disease question backed by both immunological mechanism and clinical relevance visible quickly enough to justify outside review. A manuscript can be technically careful and still difficult to route if the abstract promises one contribution while the methods, figures, data, or supplementary files support another.

The editor may be matching the manuscript to clinical allergy reviewers, immunology reviewers, asthma and airway-disease reviewers, biomarker reviewers, epidemiology reviewers, and Wiley/EAACI handling editors. That matching process can take time because the editor needs reviewers who can evaluate the central claim without rebuilding the manuscript's logic from scratch. Under Review can therefore cover both reviewer recruitment and active review.

At Allergy, the handling editor is usually making two decisions at once: whether the submission deserves outside assessment and which reviewer pool can test the manuscript fairly. The handling editor is usually testing scope, article type, evidence traceability, conflicts, reviewer availability, and whether the manuscript's strongest claim is auditable.

That editorial culture matters because the status label can look static while the handling editor checks the allergic-disease question, the immunological mechanism, and its clinical or translational relevance. Authors should prepare for comments on those components while the handling editor is still shaping the review path.

In parallel, the editor may be identifying two to three reviewers and checking whether the manuscript has the right scope for those reviewers. Recruiting reviewers can take 7 to 21 days when the topic sits between fields, depends on a specialized dataset, or requires both methodological and domain expertise. A Allergy manuscript can therefore show Under Review while the editor is still securing the right reviewer mix.

For authors, the useful question is not "has someone accepted yet?" The useful question is "if a reviewer accepts today, would the manuscript's the allergic-disease question, the immunological mechanism, and its clinical or translational relevance make the claim easy to evaluate?" That is the difference between passive waiting and productive waiting.

This is the main period in which reviewers evaluate the paper. At Allergy they are testing whether the disease question is allergy-central rather than general immunology, whether the immunological mechanism is paired with clinical or translational relevance, whether the phenotype, biomarker, challenge test, or endpoint actually aligns with the claim, and whether the statistics, ethics, and reporting standards hold. The common weak point is not a thin result; it is a mechanism-only study with no patient bridge, or a clinical dataset with too little immunology for the readership.

Active review is also where watching the portal tells you the least. A static status does not reveal whether one reviewer is late, whether the editor is waiting on a clinical-versus-mechanism reviewer, whether a reviewer declined, or whether reports are already in synthesis. The productive response is to prepare for the objection an Allergy submission most often draws.

Use the waiting window to build a response map around the allergy claim: the likely objection (usually "is the mechanism tied to clinical relevance, and is this allergy-central?"), the figure or endpoint that answers it, and the limitation language you would add. If the decision is revise, that map saves time; if it is reject, it tells you whether the work belongs at JACI, Clinical & Experimental Allergy, or a broader immunology venue.

After reports arrive, the editor turns them into a decision, which can still read as Under Review, Reviews Complete, or Decision in Process. Silence is not rejection: at Allergy it often means the editor is reconciling a mechanism reviewer with a clinical reviewer who scored the same paper differently, or weighing whether the allergy relevance is central enough.

The synthesis window is where the editor reconciles those reads. If a mechanism reviewer wants deeper immunology and a clinical reviewer wants stronger patient endpoints, the decision letter takes longer because the editor has to decide which instruction governs the revision. That delay is procedural, not a verdict.

Not automatically. The usual explanation is reviewer recruitment or a late report, not a hidden rejection, and Allergy often needs to line up both a clinical and an immunology reviewer. The useful read is whether elapsed time matches the stage: a quick move to Under Review then silence usually means one outstanding reviewer, while a later change usually means synthesis. Past 10 weeks with no movement, a polite inquiry is reasonable.

What you should not do is start re-writing in a panic or shop the paper elsewhere. Use the time to firm up the mechanism-to-clinic bridge and the alignment between your endpoint and your claim before a revise, reject-with-comments, or transfer decision arrives.

Across our pre-submission review work with Allergy manuscripts, three named status-risk patterns explain most of the productive work authors can do while the portal still says Under Review. These patterns are useful because they are tied to manuscript components a reviewer can inspect, not to generic advice about waiting.

In our pre-submission review work on Allergy manuscripts, each pattern below becomes a concrete status-window task: pressure-test whether the disease question is allergy-central, whether the mechanism ties to clinical relevance, and whether the phenotype, biomarker, or endpoint aligns with the claim before the reviewer report arrives.

The Allergy submissions that generate the most avoidable anxiety are not the weak ones. They are credible papers strong on one layer whose authors wait passively instead of building the missing mechanism-to-clinic bridge reviewers will press. Wiley/EAACI guidance explains the workflow, but it does not warn that a mechanism-only or clinic-only paper is the most common way a sound study draws a major revision.

• Allergy evidence-chain gap: The editor needs to see the allergic-disease question, the immunological mechanism, and its clinical or translational relevance without piecing together the claim from scattered files. Prepare a one-page response map that ties the central claim to figures, methods, data files, theory, and limitations.

• Allergy reviewer-routing risk: The wrong reviewer pool can make a sound paper look less convincing than it is. Use the waiting window to identify how the abstract, keywords, suggested reviewers, article type, and field framing point to clinical allergy reviewers, immunology reviewers, asthma and airway-disease reviewers, biomarker reviewers, epidemiology reviewers, and Wiley/EAACI handling editors.

• Allergy source-to-claim friction: Reviewers move quickly from headline claim to evidence traceability. Check that source data, repository links, supplementary files, figure legends, models, theory logic, and methods are easy to audit.

• Allergy revision-readiness gap: Revision speed depends on whether authors already know which objection is likely. Draft answer blocks for the two most likely reviewer concerns before the decision letter arrives.

The recurring Manusights pattern is that authors over-prepare the wrong asset while the paper is under review. At a clinical-allergy journal that usually means polishing prose when the likely objection is a missing patient bridge, or expanding the mechanism when the real problem is an endpoint that does not match the claim. For Allergy, the highest-value waiting work is to make the mechanism-to-clinic bridge and the endpoint-to-claim alignment explicit enough that a reviewer can test it without rebuilding it.

Across recent Manusights pre-submission reviews of clinical-allergy manuscripts, the useful signal was not the portal label. It was whether the draft already paired mechanism with clinical relevance and an aligned endpoint before reports arrived. That is why this page ties Under Review to the allergy-central question, the mechanism, and its clinical relevance an Allergy review must defend, instead of only defining the status phrase.

If you want a second set of eyes before the report lands, use the Allergy AI review to identify reviewer-risk issues while the manuscript is still under review.

Journal of Allergy and Clinical Immunology, Clinical and Experimental Allergy, Clinical and Translational Allergy, Frontiers in Allergy, and Allergy Asthma & Immunology Research can be cleaner routes when the study is broader immunology, more clinical-practice oriented, or narrower than Allergy expects. Do not treat transfer planning as pessimism. It is a way to shorten the next move if the decision letter confirms the current venue is one level too broad, too narrow, or too format-specific.

Official pages explain submission mechanics, but they usually do not translate a static Under Review label into the author's next practical move. This page is built from official-source review plus Manusights manuscript-risk interpretation. The reader job is narrow: "my manuscript is already in the portal; what does this status mean and what should I do while waiting?"

The review link sits below the status definition, timeline, follow-up threshold, and source limitations on purpose, so the page serves the waiting author first and leaves pre-upload mechanics to the submission guide.

Source limitations: this page uses public official-source guidance plus Manusights manuscript-risk interpretation; it cannot see the private reviewer invitations, report status, or handling-editor notes inside your manuscript record.

Wiley and EAACI's public pages can tell you the Allergy portal, the article-scope language, the submission route, and the broad review policy. They cannot tell you whether your specific paper has reviewers assigned, whether one is late, or whether the editor is leaning toward a revise or a transfer. That is why this page separates official-source facts from interpretation: the official sources anchor the workflow; the Manusights layer is the mechanism-and-clinical risk read.

Official sources used for this Under Review interpretation:

• journalallergy.com
• Wiley journal page
• Wiley submission portal
• Wiley author instructions
• Wiley author instructions

• Allergy hub
• Allergy submission guide
• Allergy metrics
• how to avoid desk rejection at Allergy
• journal-selection guide
• not-ready warning signs
• cover-letter guide

Before you wait another month, run a Allergy reviewer-risk check and prepare the revision map reviewers are most likely to force you to build later.

Source-specific notes from this research pass:

• The Allergy journal site and Wiley Online Library identify the journal and route authors to Wiley submission infrastructure.
• Wiley author help says authors should use the journal homepage and author guidelines to locate the submission system and requirements.
• Wiley submission guidance emphasizes file checks, journal-specific author guidelines, and supported manuscript formats.